Demegen Overview

  • Founded
  • 1992

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

  • Investments
  • 1

Demegen General Information

Description

Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.

Contact Information

Website
www.demegen.com
Formerly Known As
Demeter BioTechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Par Advance Technologies
Primary Office
  • 100 Technology Drive
  • Suite 440B
  • Pittsburgh, PA 15219
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Demegen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fun
Biotechnology
Pittsburgh, PA
000
000000&0 000

000000

ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000000000000
Salt Lake City, UT
0000 As of 0000
00000
000000 - 000 00000

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000000
Aurora, CO
0 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Demegen Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Myriad Genetics Corporation Salt Lake City, UT 0000 00000 000000 - 000 00000
00000000000 Corporation Aurora, CO 0 0000000000
00000000 000000000 Venture Capital-Backed Wuxi, China 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Pensacola, FL 00 00000 00000000000 00000
To view Demegen’s complete competitors history, request access »

Demegen Patents

Demegen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20020022048-A1 Bioerosable film; adhesion to mucous membranes Abandoned 26-May-2000 000000000 0
EP-1328234-A1 Methods for treating cystic fibrosis Withdrawn 08-Jan-1999 00000000000
AU-3344500-A Methods for treating cystic fibrosis Abandoned 08-Jan-1999 00000000000
US-6528488-B2 Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment Expired - Lifetime 08-Jan-1999 00000000000 0
US-20020077282-A1 Therapy of cystic fibrosis in a mammal by administering mammal an effective amount of a histatin or its fragment Granted 08-Jan-1999 C07K14/4723
To view Demegen’s complete patent history, request access »

Demegen Executive Team (1)

Name Title Board Seat Contact Info
Richard Ekstrom Chief Executive Officer
To view Demegen’s complete executive team members history, request access »

Demegen Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 01-Jan-2001 0000000000 Other Pharmaceuticals and Biotechnology
To view Demegen’s complete acquisitions history, request access »